Skip to content
2000
Volume 13, Issue 5
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Present-day is developing in many fields. Many pathological processes are better understood, including carcinogenesis. Consequently, the failure of pharmacotherapy aimed at cancerous diseases is becoming explainable. At the same time, new anticancer drugs continue to be introduced. Anthracycline antibiotics are a well-known and widely used group of anticancer drugs. However, in addition to their efficiency they demonstrate severe side effects compounded by the appearance of resistant cells. Therefore, the search for new anthracycline derivatives with improved pharmacodynamic properties and fewer adverse effects is in progress, delivering promising results.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/1389557511313050001
2013-04-01
2025-09-06
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/1389557511313050001
Loading

  • Article Type:
    Research Article
Keyword(s): Anthracycline antibiotics; cancer; cardiotoxicity; drugs modifications
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test